Allergy

A group of pediatric patients were able to sustain desensitization 4 weeks after stopping the daily oral immunotherapy.

How far in advances of care have we come, what issues are most pressing in the field now, and what specialties with be involved in future meetings?

The introduction of biologics such as dupilumab have opened avenues of care for patients with overlapping disease.

The biologic's indications for inflammatory diseases are greatly varied and still developing, and it owes some of that to recent advances in disease prognosis.

The AAAAI 2019 president explains why research is already dedicated toward improving investigative peanut allergens.

The Regeneron VP explains how dupilumab could possibly serve as a complimentary therapy to Aimmune's investigative food allergy therapy.

Results showed a statistically significant difference in responder rate between active treatment and placebo but didn’t meet a prespecified threshold for clinical significance.

The Program Chair explains how the meeting has improved over 3 decades, and highlights his favorite sessions to come at the 2019 meeting.

The intranasal epinephrine spray is being developed for use with Intravail, a nasal absorption enhancing technology.

The EPIT skin patch is still seeking indication as the first peanut allergy desensitization therapy to reach the market.

A new survey study found that less than half of food allergies reported by adults have actually been diagnosed by a physician.

Children often develop food allergies prior to developing asthma, and the former condition is associated with a greater risk of the latter condition in later life.

Rapidly accumulating evidence indicates that delayed introduction of allergenic foods may have contributed to the unexplained rise in food allergy rates over the past 20 years.

Asthma is the most common chronic disease of childhood. Cellphones might help improve its management.

The biologic AR101 was previously shown to significantly desensitize peanut allergies in a pediatric and adolescent patient population.

Results may ease concerns for many physicians and patients who live in colder climates.

A 48-year-old man presents with severe atopic dermatitis that he’s had since childhood. Can allergy shots succeed where standard treatments failed?

The AR101 oral therapy—a biologic designed to desensitize peanut allergies, manufactured by Aimmune Therapeutics—is anticipated to be submitted for FDA approval in the next month.

Demystifying the oral food challenge starts with understanding its risks and benefits.

Study co-author Nicola Alexander Hanania, MD, explains what the new data means for practicing pulmonologists and allergists.

Busse explains the importance of having an additional treatment option and covers best practices for prescribing.

In 2017, roughly 5% of newborns had a peanut allergy. That’s a stark increase from the roughly 1% that characterized previous decades, according to researchers.

Researchers sought to balance the cost of autoinjectors with their lifesaving potential, and then boil the results down to an agreeable number. Here’s where they landed.

An updated epidemiological review paints a concerning picture of pediatric cow’s milk allergy in the US.

Long-term lung inflammation associated with allergen exposure is linked to the development of anxiety later in adulthood, according to a new study.